C4 Therapeutics Stockholders Elect Directors, Approve Plan Amendment
C4 Therapeutics, Inc. held its Annual Meeting of Stockholders on June 24, 2026. Stockholders elected Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors. They also approved the non-binding advisory vote on executive compensation and ratified KPMG LLP as the independent registered public accounting firm for 2026. Additionally, an amendment to the Company's 2020 Stock Option and Incentive Plan was approved, modifying the evergreen provision to include outstanding pre-funded warrants.
Key Highlights
- Stockholders elected Andrew J. Hirsch as Class III director with 47,797,964 votes For.
- Stephen Fawell, Ph.D., was elected Class III director with 47,811,414 votes For.
- Utpal Koppikar was elected Class III director with 46,491,892 votes For.
- Non-binding advisory vote to approve executive compensation passed with 54,935,574 votes For.
- KPMG LLP was ratified as independent auditor for 2026 with 76,891,210 votes For.
- Amendment to the 2020 Stock Option and Incentive Plan was approved with 33,713,572 votes For.
Price Impact
More from CCCC
C4 Therapeutics Secures Roche DAC Partnership with $20M Upfront, $1B+ Milestones
C4 Therapeutics Q2 Net Loss $23.6M, EPS $0.18; Cemsidomide Trials On Track
C4 Therapeutics Presents Promising Phase 1 Data for Cemsidomide in Multiple Myeloma